When diagnosed with Multiple System Atrophy (MSA), one of the most challenging things for the individual and their family, is to understand the wide range of symptoms that can come with it.
MSA is a rare and fast-progressing neurological condition that can affect many body functions. It can affect movement, ‘automatic functions’ such as blood pressure regulation, bladder control and breathing, and cognitive and emotional health.
Knowing and understanding the full range of symptoms can help people living with MSA, or their loved ones, to feel more informed and better prepared.
The purpose of this blog is to help with that understanding, by providing a clear and comprehensive overview of MSA symptoms. It also discusses which symptoms often appear first, how symptoms differ between MSA subtypes, and how they typically progress as the disease develops. It is intended for anyone affected by MSA, as well as those who are simply interested in learning more about this complex condition.
Multiple System Atrophy (MSA) is a rare and progressive neurodegenerative disorder. It causes nerve cells to deteriorate over time in several key areas of the brain. These regions are responsible for controlling movement, balance, coordination, and involuntary functions such as blood pressure regulation, digestion, and breathing. As more nerve cells are lost over time, the body struggles to carry out these essential functions. 1, 2, 3
There are two main types of MSA, classified based on the main symptoms a person experiences, especially in the early stages:
This blog takes a closer look at the different symptoms MSA can present, helping readers gain a broader understanding of how the condition can impact various body functions. Learn more about causes, diagnosis, and treatments in our blog: Understanding Multiple System Atrophy.
Multiple System Atrophy (MSA) symptoms most commonly begin between the ages of 50 and 60. However, they can start anytime from the age of 30. 2, 3, 4 Symptoms often progress rapidly over the course of 5 to 10 years. 2
People with MSA may have several symptoms at once. These may affect:
For most people with MSA (around 70%), symptoms involving involuntary or automatic body functions appear first. These early symptoms are caused by damage to the autonomic nervous system. This is the part of the nervous system that controls involuntary or automatic functions such as blood pressure regulation, bladder and bowel control, digestion, temperature regulation, and sexual function. These are functions the body normally manages without conscious effort.
These can show up months or even years before movement issues begin. 1, 2, 5, 6 They can include:
Multiple System Atrophy (MSA) damages the parts of the brain that normally helps regulate blood pressure automatically. As a result, the body can’t properly adjust blood pressure in response to certain activities.
MSA can cause a sudden drop in blood pressure in situations like:
Symptoms of low blood pressure can include:
Some people with MSA experience high blood pressure when lying down, especially at night, a condition called supine hypertension. It affects about half of those with orthostatic hypotension. Supine hypertension may not always cause symptoms. But when it does, it can lead to:
Sexual dysfunction is a common, and often early, symptom of Multiple System Atrophy (MSA). It happens because MSA affects the autonomic nervous system, which control automatic body functions, including sexual response.
In men, erectile dysfunction is often the first sign of MSA. This means trouble getting or keeping an erection firm enough for sex. 5, 6, 14, 15
On average, this symptom may appear about four years before an official diagnosis of MSA. 6 Men may also experience:
In women, sexual dysfunction can include:
Bladder problems are very common in people with Multiple System Atrophy (MSA). They are often one of the earliest signs of the disease. 1, 6, 15
Early bladder symptoms may include:
As the disease progresses, people may also have difficulty fully emptying the bladder, which can lead to urine left behind, raising the risk of urinary tract infections, kidney swelling, and even kidney damage. 17
Along with bladder symptoms, bowel problems are also common in people with Multiple System Atrophy (MSA). 1, 5
The most frequent bowel issue is constipation. This can start early in the disease and may include:
In some cases, especially in later stages of MSA, people may also experience bowel incontinence, which means accidental loss of stool. 6, 18, 19
Many people with Multiple System Atrophy (MSA) experience sleep problems. In about 20% of cases, sleep-related symptoms can be among the first signs of the disease. 6
The most common is rapid eye movement sleep behavior disorder (RBD), which is also frequently an early symptom of the disease. People with RBD act out vivid and sometimes violent dreams while sleeping without being aware of it. Movements may include kicking, punching, flailing, or shouting during sleep. 10, 20, 21
Other sleep issues in MSA may include:
MSA can also cause breathing problems during sleep, including:
People with Multiple System Atrophy (MSA) may have trouble regulating their body temperature due to a reduced ability to sweat. This condition is known as anhidrosis. 1, 5
Sweating is the body’s natural way to cool down. When the sweat glands don’t work properly, as in some cases of MSA, it can lead to overheating or feeling unusually hot or cold.
In MSA, this can happen in different ways:
When the body can’t sweat normally, it can cause problems like:
In Multiple System Atrophy (MSA), movement-related symptoms usually appear after autonomic symptoms like blood pressure or bladder issues. However, in about 10% of people, mild movement symptoms may appear early in the disease. 6
Movement symptoms vary depending on the type of MSA a person has:
Over time, people with either type of MSA often develop a mix of symptoms. For example, more than half of those with MSA-C eventually develop Parkinsonian features, and many with MSA-P also experience cerebellar symptoms. 17, 23, 24, 25, 26
Parkinsonian features are typical of MSA-P. They often resemble those seen in Parkinson’s disease. In some cases, symptoms may start on one side of the body, but typically spread quickly to both sides 1, 17
Parkinsonian symptoms may include:
Multiple System Atrophy (MSA) progresses faster than Parkinson’s Disease. Many people with MSA-P require walking aids within three years of symptom onset, and up to 60% may need a wheelchair within five years. 17
Cerebellar symptoms are typical of MSA-C. They may include:
Cognitive problems affect how the brain processes information. This can impact memory, attention, language, or problem-solving. Some people with MSA develop mild cognitive issues, while others may notice more severe changes over time. 1, 5, 10
The most common cognitive MSA symptoms include:
This involves the ability to plan, organize, stay on task, and switch between ideas or activities. About 50% of people with MSA have trouble in this area. 10 Common signs include:
This includes:
MSA can also affect how people understand and move through space, which is called visuospatial ability. This means people may:
People with Multiple System Atrophy (MSA) may experience emotional changes that affect how they feel, act or respond to situations. It may include:
Multiple System Atrophy (MSA) is a progressive neurodegenerative disorder caused by the deterioration of nerve cells in key areas of the brain. It affects involuntary (autonomic) functions, movement, and, in some cases, thinking and emotions. Symptoms usually begin between the ages of 50 and 60, but can appear as early as 30.
In about 70% of people, the first signs involve autonomic issues such as blood pressure problems, sexual dysfunction, bladder or bowel difficulties, sleep disturbances, and reduced ability to sweat. Movement symptoms typically appear later and vary by type. MSA-P (parkinsonian type) causes stiffness, tremors, and slowed movement, while MSA-C (cerebellar type) affects coordination, leading to clumsiness, wide-based walking, and jerky eye movements.
Some people also experience cognitive problems, such as memory loss or difficulty understanding spatial relationships. Emotional changes are also common and may include depression, anxiety, or episodes of uncontrollable crying or laughing. MSA tends to progress quickly, with symptoms typically worsening over five to ten years.
If you want to explore clinical trial options, you can book a call with a Patient Navigator to discover your options and learn more about clinical trials.
At myTomorrows, we have a team of Patient Navigators, who are multi-lingual professionals with a medical background, who can help you to explore your treatment options and support you through your journey.
[1] Cleveland Clinic, “Multiple System Atrophy (MSA): Symptoms & Treatment.” Accessed: May 14, 2025. [Online]. Available: https://my.clevelandclinic.org/health/diseases/17250-multiple-system-atrophy
[2] National Institute of Neurological Disorders and Stroke, “Multiple System Atrophy.” Accessed: Apr. 28, 2025. [Online]. Available: https://www.ninds.nih.gov/health-information/disorders/multiple-system-atrophy
[3] NHS, “Multiple system atrophy (MSA).” Accessed: Apr. 28, 2025. [Online]. Available: https://www.nhs.uk/conditions/multiple-system-atrophy/
[4] NHS inform “Multiple system atrophy (MSA).” Accessed: Jul. 11, 2025. [Online]. Available: https://www.nhsinform.scot/illnesses-and-conditions/brain-nerves-and-spinal-cord/multiple-system-atrophy-msa/
[5] Mayo Clinic, “Multiple system atrophy.” Accessed: Apr. 28, 2025. [Online]. Available: https://www.mayoclinic.org/diseases-conditions/multiple-system-atrophy/symptoms-causes/syc-20356153
[6] J. H. McKay and W. P. Cheshire, “First symptoms in multiple system atrophy,” Clinical Autonomic Research, vol. 28, no. 2, p. 215, Apr. 2018, doi: 10.1007/S10286-017-0500-0.
[7] Cleveland, “Postprandial Hypotension.” Accessed: Jul. 14, 2025. [Online]. Available: https://my.clevelandclinic.org/health/diseases/postprandial-hypotension
[8] A. Awosika, U. Adabanya, R. M. Millis, A. E. Omole, and J. H. Moon, “Postprandial Hypotension: An Underreported Silent Killer in the Aged,” Cureus, vol. 15, no. 2, p. e35411, Feb. 2023, doi: 10.7759/CUREUS.35411.
[9] T. Fukushima et al., “Role of intestinal peptides and the autonomic nervous system in postprandial hypotension in patients with multiple system atrophy,” J Neurol, vol. 260, no. 2, pp. 475–483, Feb. 2013, doi: 10.1007/S00415-012-6660-X/METRICS.
[10] V. Chelban et al., “An update on MSA: premotor and non-motor features open a window of opportunities for early diagnosis and intervention,” J Neurol, vol. 267, no. 9, p. 2754, Sep. 2020, doi: 10.1007/S00415-020-09881-6.
[11] J. Jordan and I. Biaggioni, “Diagnosis and Treatment of Supine Hypertension in Autonomic Failure Patients With Orthostatic Hypotension,” The Journal of Clinical Hypertension, vol. 4, no. 2, p. 139, 2007, doi: 10.1111/J.1524-6175.2001.00516.X.
[12] J. A. Palma et al., “The impact of supine hypertension on target organ damage and survival in patients with synucleinopathies and neurogenic orthostatic hypotension,” Parkinsonism Relat Disord, vol. 75, pp. 97–104, Jun. 2020, doi: 10.1016/j.parkreldis.2020.04.011.
[13] Healthline, “Supine Hypertension: Causes, Symptoms, Diagnosis, Treatment.” Accessed: Jul. 14, 2025. [Online]. Available: https://www.healthline.com/health/high-blood-pressure-hypertension/supine-hypertension#causes
[14] MSA Trust, “Factsheet. Relationships, Sex and multiple system atrophy”, Accessed: Jul. 15, 2025. [Online]. Available: https://www.msatrust.org.uk/wp-content/uploads/2015/11/FS200-V1.7-Relationships-Sex-and-MSA.pdf
[15] Y. Luo et al., “Autonomic dysfunction in multiple system atrophy: from pathophysiology to clinical manifestations,” Ann Med, vol. 57, no. 1, p. 2488111, Dec. 2025, doi: 10.1080/07853890.2025.2488111;CTYPE:STRING:JOURNAL.
[16] C. Raccagni et al., “Female sexual dysfunction in multiple system atrophy: a prospective cohort study,” Clinical Autonomic Research, vol. 31, no. 6, p. 713, Dec. 2021, doi: 10.1007/S10286-021-00825-2.
[17] I. Stankovic, A. Fanciulli, V. Sidoroff, and G. K. Wenning, “A Review on the Clinical Diagnosis of Multiple System Atrophy,” The Cerebellum 2022 22:5, vol. 22, no. 5, pp. 825–839, Aug. 2022, doi: 10.1007/S12311-022-01453-W.
[18] C. F. Craig, D. I. Finkelstein, R. M. McQuade, and S. Diwakarla, “Understanding the potential causes of gastrointestinal dysfunctions in multiple system atrophy,” Neurobiol Dis, vol. 187, Oct. 2023, doi: 10.1016/j.nbd.2023.106296.
[19] Bladder & Bowel Community, “Multiple System Atrophy (MSA) | Bladder & Bowel Community.” Accessed: Jul. 15, 2025. [Online]. Available: https://www.bladderandbowel.org/bladder/bladder-conditions-and-symptoms/msa/
[20] H. Wang, T. Zhang, and W. Fan, “Prevalence and impact of rapid eye movement sleep behavior disorder in multiple system atrophy: a systematic review and meta-analysis,” Front Neurol, vol. 15, p. 1453944, Oct. 2024, doi: 10.3389/FNEUR.2024.1453944/BIBTEX.
[21] L. Ferini-Strambi and S. Marelli, “Sleep dysfunction in multiple system atrophy,” Curr Treat Options Neurol, vol. 14, no. 5, pp. 464–473, Oct. 2012, doi: 10.1007/S11940-012-0189-2,.
[22] “Anhidrosis (Lack of Sweat): Symptoms, Causes & Treatment.” Accessed: Jul. 08, 2025. [Online]. Available: https://my.clevelandclinic.org/health/diseases/15891-anhidrosis-lack-of-sweat
[23] B. Cui, W. Zheng, S. Ren, Z. Chen, and Z. Wang, “Differentiation of Cerebellum-Type and Parkinson-Type of Multiple System Atrophy by Using Multimodal MRI Parameters,” Front Aging Neurosci, vol. 13, p. 687649, Aug. 2021, doi: 10.3389/FNAGI.2021.687649/BIBTEX.
[24] M. Carmona-Abellan et al., “Multiple system atrophy: Clinical, evolutive and histopathological characteristics of a series of cases,” Neurología, vol. 38, no. 9, pp. 609–616, Nov. 2023, doi: 10.1016/J.NRL.2021.04.007.
[25] K. A. Jellinger, “Heterogeneity of Multiple System Atrophy: An Update,” Biomedicines, vol. 10, no. 3, p. 599, Mar. 2022, doi: 10.3390/BIOMEDICINES10030599.
[26] G. K. Wenning et al., “The natural history of multiple system atrophy: a prospective European cohort study,” Lancet Neurol, vol. 12, no. 3, pp. 264–274, Mar. 2013, doi: 10.1016/S1474-4422(12)70327-7.
[27] M. D. Garcia, J. S. Pulido, E. A. Coon, and J. J. Chen, “Ocular features of multiple system atrophy,” Journal of Clinical Neuroscience, vol. 47, pp. 234–239, Jan. 2018, doi: 10.1016/j.jocn.2017.10.028.
[28] R. A. Armstrong, “Visual signs and symptoms of multiple system atrophy,” Clin Exp Optom, vol. 97, no. 6, pp. 483–491, Nov. 2014, doi: 10.1111/CXO.12206;WGROUP:STRING:PUBLICATION.
About the author
Medical Content Writer at myTomorrows
Dr. Andrea Enguita Marruedo holds a master’s in Genetics and Cell Biology from the Autonomous University of Madrid and a PhD in Developmental Biology from the Erasmus Medical Centre in Rotterdam. She began her career in medical writing after completing her doctoral studies and has covered a wide range of therapeutic areas, including neuromuscular and neurodegenerative disorders, cancer, and diabetes.
Andrea specializes in translating complex biomedical topics into clear, accessible content for patients and healthcare professionals. With a strong research background and a passion for science communication, she is committed to delivering accurate, well-referenced content that supports greater awareness and understanding of medical topics among patients, caregivers, and clinicians.
Andrea Enguita 13 Aug 2025